Entering text into the input field will update the search result below

Monopar initiates early-stage camsirubicin advanced soft tissue sarcoma study

Human Cancer Cell
luismmolina/E+ via Getty Images

  • Monopar Therapeutics (NASDAQ:MNPR) announces that its Phase 1b open-label dose-escalation trial of camsirubicin in the U.S. is active and recruiting patients.
  • The trial is evaluating the safety and anti-tumor activity of increasing doses of camsirubicin in

Recommended For You

More Trending News

About MNPR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MNPR--
Monopar Therapeutics Inc.